Рилвегостомиг
RilvegostomigМНН
Rec. INN (наименование, зарегистрированное ВОЗ)
CAS
2640305-01-5
Химическое название
immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)] and anti-[Homo sapiens TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized and Homo sapiens monoclonal antibody, bispecific;
gamma1 heavy chain anti-PDCD1 (1-452) [VH humanized (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), P116>S (336) (236-345), CH3 Y5>C (354), E12 (361), M14 (363), T22>S (371), L24>A (373), Y86>V (412) (346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain anti-PDCD1 (1'-219') [V-KAPPA humanized (Homo sapiens IGKV3D-7*01 (81.1%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')];
gamma1 heavy chain anti-TIGIT (1''-451'') Homo sapiens [VH (Homo sapiens IGHV3-30*01 (96.9%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1''-121'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v32 CH3 W22 (knob) (CH1 F5>C (130), R120 (218) (122''-219''), hinge 1-15 C5>V (224) (220''-234''), CH2 L1.3>F (238), L1.2>E (239), P116>S (335) (235''-344''), CH3 S10>C (358), E12 (360), M14 (362), T22>W (370) (345''-449''), CHS (450''-451'')) (122''-451'')], (130''-125''')-disulfide with lambda light chain anti-TIGIT (1'''-219''') Homo sapiens [V-LAMBDA (Homo sapiens IGLV1-44*01 (92.6%) -IGLJ7*01 (90%) F118>L (101) , CDR-IMGT [8.3.11] (26-33.51-53.90-100)) (1'''-110''') -Homo sapiens IGLC2*01 (98.1%) S10>C (125), C126>V (215) (111'''-216''')]; heterodimer (231-230'':234-233'': 354-358'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-CAT-S, glycoform alfa
gamma1 heavy chain anti-PDCD1 (1-452) [VH humanized (Homo sapiens IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole) (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 L1.3>F (239), L1.2>E (240), P116>S (336) (236-345), CH3 Y5>C (354), E12 (361), M14 (363), T22>S (371), L24>A (373), Y86>V (412) (346-450), CHS (451-452)) (123-452)], (225-219')-disulfide with kappa light chain anti-PDCD1 (1'-219') [V-KAPPA humanized (Homo sapiens IGKV3D-7*01 (81.1%) -IGKJ2*02 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158), V101 (196) (113'-219')];
gamma1 heavy chain anti-TIGIT (1''-451'') Homo sapiens [VH (Homo sapiens IGHV3-30*01 (96.9%) -(IGHD) -IGHJ6*01 (94.4%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1''-121'') -Homo sapiens IGHG1*03, G1m3, nG1m1, G1v32 CH3 W22 (knob) (CH1 F5>C (130), R120 (218) (122''-219''), hinge 1-15 C5>V (224) (220''-234''), CH2 L1.3>F (238), L1.2>E (239), P116>S (335) (235''-344''), CH3 S10>C (358), E12 (360), M14 (362), T22>W (370) (345''-449''), CHS (450''-451'')) (122''-451'')], (130''-125''')-disulfide with lambda light chain anti-TIGIT (1'''-219''') Homo sapiens [V-LAMBDA (Homo sapiens IGLV1-44*01 (92.6%) -IGLJ7*01 (90%) F118>L (101) , CDR-IMGT [8.3.11] (26-33.51-53.90-100)) (1'''-110''') -Homo sapiens IGLC2*01 (98.1%) S10>C (125), C126>V (215) (111'''-216''')]; heterodimer (231-230'':234-233'': 354-358'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-CAT-S, glycoform alfa
Структура
Иностранные названия
- Rilvegostomigum (латинское)
- Rilvegostomig (английское)
- Rilvegostomig (немецкое)
- Rilvegostomig (французское)
- Rilvegostomig (испанское)
Подробнее по теме
Узнайте дополнительные сведения о действующем веществе Рилвегостомиг: